NYSE:CTLT - Catalent Stock Price, Price Target & More

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) announced its quarterly earnings data on Tuesday, May, 1st. The company reported $0.41 EPS for the quarter, beating the Zacks' consensus estimate of $0.35 by $0.06. The firm earned $627.90 million during the quarter, compared to analysts' expectations of $610.47 million. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The company's revenue for the quarter was up 17.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.38 earnings per share. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Monday, August, 27th 2018. View Earnings Estimates for Catalent.

Catalent issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $1.57-$1.74 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.67. The company issued revenue guidance of $2.42-$2.48 billion, compared to the consensus revenue estimate of $2.45 billion.

14 equities research analysts have issued 1-year price objectives for Catalent's shares. Their forecasts range from $38.00 to $50.00. On average, they anticipate Catalent's share price to reach $45.8182 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Ratings for Catalent.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Catalent include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX) and SAGE Therapeutics (SAGE).

Press coverage about CTLT stock has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalent earned a news impact score of 0.17 on Accern's scale. They also gave headlines about the company an impact score of 47.56 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Catalent's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.01%), State of Alaska Department of Revenue (0.01%), Atria Investments LLC (0.01%) and Fortaleza Asset Management Inc. (0.00%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Fortaleza Asset Management Inc.. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Atria Investments LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $43.29.

Catalent has a market capitalization of $5.79 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $1.35 on an earnings per share basis. Catalent employs 10,800 workers across the globe.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]